New HIV vaccine could expose latent virus, kill it

CHUKWUMA MUANYA | April 15, 2019 | 22 views

Antiretroviral therapy may soon be obsolete, as scientists have successfully used immune cells to kick the dormant form of Human Immuno-deficiency Virus (HIV) out of its hiding place and destroy it. The findings may soon lead to an HIV vaccine. With the help of antiretroviral therapy, over half of these people now have a very low level of the virus. This means that they can no longer transmit it to other people. Antiretroviral therapy can keep HIV in check so well that the virus is near-undetectable in the blood. However, HIV continues to “live” in latent form, so people with it must keep taking the medications to prevent it from flaring up. 

Spotlight

Igenomix

IGENOMIX is a company that provides advanced services in reproductive genetics. Our broad experience and qualifications make us one of the global leaders in this field. Our constant efforts in R&D, led by Prof. Dr. Carlos Simón (2011 Jaime I award-winner for Clinical Research), enable us to create and develop specific tools to support professionals in the reproductive medicine field.

OTHER ARTICLES
MEDICAL

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | August 2, 2021

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More
MEDICAL

Top 10 biotech IPOs in 2019

Article | June 22, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
INDUSTRIAL IMPACT

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | January 20, 2021

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Spotlight

Igenomix

IGENOMIX is a company that provides advanced services in reproductive genetics. Our broad experience and qualifications make us one of the global leaders in this field. Our constant efforts in R&D, led by Prof. Dr. Carlos Simón (2011 Jaime I award-winner for Clinical Research), enable us to create and develop specific tools to support professionals in the reproductive medicine field.

Related News

Severity of COVID-19 May Depend on Your Individual Genetic Variation in Immune System

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte antigen genes that are involved in recognizing pathogens, vary from person to person. Variations can influence how well the immune system recognizes a given pathogen. Poor recognition of SARS-CoV-2 could cause a person to be more vulnerable to the virus. “In particular, understanding how variation in HLA [a component of the immune system containing multiple genes] may affect the course of COVID-19 could help identify individuals at higher risk from the disease,” according to the authors of the new study.

Read More

Biotech stocks surge as people are hungry for good news on the coronavirus

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT. News that biotech firm Moderna received $483 million in federal funds for its vaccine development also boosted the sector higher.

Read More

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

Severity of COVID-19 May Depend on Your Individual Genetic Variation in Immune System

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte antigen genes that are involved in recognizing pathogens, vary from person to person. Variations can influence how well the immune system recognizes a given pathogen. Poor recognition of SARS-CoV-2 could cause a person to be more vulnerable to the virus. “In particular, understanding how variation in HLA [a component of the immune system containing multiple genes] may affect the course of COVID-19 could help identify individuals at higher risk from the disease,” according to the authors of the new study.

Read More

Biotech stocks surge as people are hungry for good news on the coronavirus

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT. News that biotech firm Moderna received $483 million in federal funds for its vaccine development also boosted the sector higher.

Read More

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

Events